France hits Roche and Novartis with €444 million fine

France’s Competition Authority has fined Roche, Novartis and Genentech a total of €444 million for abusing their collective dominance by preventing the entry of a cheaper eye treatment drug into the French market.


Get unlimited access to all Global Competition Review content